Literature DB >> 30571236

Clinical Benefit of Treatment of Stage-1, Low-Risk Hypertension.

Chan Joo Lee1, Jiin Ryu2, Hyeon-Chang Kim3, Dong-Ryeol Ryu4, Sang-Hyun Ihm5, Yong-Jin Kim6, Jin-Ho Shin7, Wook Bum Pyun8, Hyoung-Soo Kang9, Jong-Heon Park9, Jinseub Hwang2, Sungha Park10.   

Abstract

Evidence about the benefits of treating uncomplicated, low-risk, stage-1 hypertension is lacking. The study aimed to investigate the association between mean blood pressure (BP) and clinical outcomes, and to determine optimal BPs in treated, low-risk, stage-1 hypertension. From the National Health Insurance Service Health Examination Database, patients with stage-1 hypertension between 2005 and 2006 were selected. They had a systolic BP of 140 to 159 mm Hg or diastolic BP of 90 to 99 mm Hg. Patients were grouped as controlled (mean BP <140/90 mm Hg; n=99 301) and uncontrolled (mean BP ≥140/90 mm Hg; n=49 460) according to their mean BP recorded during the follow-up health examination. All-cause mortality and cardiovascular outcomes were examined. Mean BPs in the controlled and uncontrolled groups were 131.1/80.9 and 144.6/86.8 mm Hg, respectively. Controlled BP was associated with significantly lower risks of all-cause mortality, all stroke, hemorrhagic stroke, ischemic stroke, and end-stage renal disease. Subgroup analysis demonstrated benefits of controlled BP in hypertensive patients aged <50 years for all-cause mortality, all stroke, hemorrhagic stroke, ischemic stroke, and end-stage renal disease, with no significant interaction according to age. The BP associated with the lowest risk of all-cause mortality was 120 to <130 mm Hg (systolic BP) and 70 to <80 mm Hg (diastolic BP). There was an increased risk of myocardial infarction in patients with mean systolic BP <120 mm Hg and diastolic BP <80 mm Hg. BP <140/90 mm Hg was associated with a significant reduction in the risk of mortality, stroke, and end-stage renal disease, with the lowest mortality risk at BP ranges of 120 to <130 and 70 to <80 mm Hg.

Entities:  

Keywords:  blood pressure; hypertension; mortality; myocardial infarction; stroke

Mesh:

Substances:

Year:  2018        PMID: 30571236     DOI: 10.1161/HYPERTENSIONAHA.118.11787

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Maintenance phase of a physical activity intervention in older kidney transplant recipients: A 12-month follow-up.

Authors:  Tara O'Brien; Alai Tan; Karen Rose; Brian Focht; Reem Daloul
Journal:  Geriatr Nurs       Date:  2021-11-03       Impact factor: 2.361

2.  Blood pressure control in heart failure: Is everything black and white?

Authors:  Evgeny Belyavskiy; Elisabeth Pieske-Kraigher; Marijana Tadic
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-07-08       Impact factor: 3.738

3.  Ten-year trends of hypertension treatment and control rate in Korea.

Authors:  Kwang-Il Kim; Eunjeong Ji; Jung-Yeon Choi; Sun-Wook Kim; Soyeon Ahn; Cheol-Ho Kim
Journal:  Sci Rep       Date:  2021-03-26       Impact factor: 4.379

Review 4.  Cardiovascular Research Using the Korean National Health Information Database.

Authors:  Eue Keun Choi
Journal:  Korean Circ J       Date:  2020-05-20       Impact factor: 3.243

5.  Differential Control Rate of Systolic and Diastolic Blood Pressure among Korean Adults with Hypertension: the Sixth Korean National Health and Nutrition Examination Survey, 2013-2015 (KNHANES VI).

Authors:  So Mi Jemma Cho; Hokyou Lee; Wook Bum Pyun; Hyeon Chang Kim
Journal:  Korean Circ J       Date:  2019-06-03       Impact factor: 3.243

Review 6.  Ideal Target Blood Pressure in Hypertension.

Authors:  Sungha Park
Journal:  Korean Circ J       Date:  2019-11       Impact factor: 3.243

7.  Monotherapy treatment with chlorthalidone or amlodipine in the systolic blood pressure intervention trial (SPRINT).

Authors:  Deep Vakil; Stavros Zinonos; John B Kostis; Jeanne M Dobrzynski; Nora M Cosgrove; Abel E Moreyra; William J Kostis
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-06-02       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.